SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline include galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

Earnings data Q1 2023

Earnings data Q2 2023

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

Phase 3 REGAL GPS AML Study on Track for Interim Analysis by Late 2023/Early 2024

SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update

Safety and Immunogenicity Examined in Phase 1 Trial of GPS plus Anti–PD-1 Nivolumab in Patients with WT1-Expressing Relapsed Ovarian Cancer in the Post-Salvage Setting

SELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed Journal

Sellas Life Sciences Group Inc. SLS, -3.40% said Friday that it raised $20.0 million, through the public sale of common shares and warrants to buy stock. Shares of the biopharmaceutical company, which is focused on cancer treatments, plummeted 43.1% in premarket trading, after the offering was initially announced without terms late Thursday.

Sellas Life Sciences raises $20 million from public offering of stock, warrants

NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the pricing of its previously announced underwritten public offering of 7,220,217 shares of its common stock and accompanying warrants to purchase up to 7,220,217 shares of common stock at a combined public offering price of $2.77 per share and accompanying warrant. The warrants to purchase shares of common stock have an exercise price of $2.77 per share, are immediately exercisable and will expire five years from the date of issuance. All of the securities in the offering will be sold by SELLAS, with gross proceeds to SELLAS expected to be $20.0 million before deducting underwriting discounts and commissions and offering expenses. The offering is expected to close on February 28, 2023, subject to the satisfaction of customary closing conditions.

SELLAS Life Sciences Announces Pricing of $20.0 Million Underwritten Public Offering

SELLAS Life Sciences (NASDAQ: SLS ) stock is falling on Friday after the late-stage clinical biopharmaceutical company announced a proposed public offering. According to a press release, SELLAS Life Sciences intends to offer up shares of SLS stock, as well as warrants to purchase shares of the stock.

Why Is SELLAS Life Sciences (SLS) Stock Down 38% Today?

NEW YORK, Feb. 23, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. All of the securities in the offering will be sold by SELLAS.

SELLAS Life Sciences Announces Proposed Underwritten Public Offering

Galena Biopharma, Inc. (SLS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Galena Biopharma, Inc. (SLS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Event will Feature Presentation from Hematology Oncology Expert Omer Jamy, MD, Phase 3 REGAL Study Principal Investigator at the University of Alabama Participating Site

SELLAS Life Sciences to Host Key Opinion Leader Webinar on Galinpepimut-S Acute Myeloid Leukemia Program

Andrew Elnatan Brings Nearly Three Decades of Global Regulatory Experience with Successful Breakthrough Therapy Designation and Global Drug Approvals Andrew Elnatan Brings Nearly Three Decades of Global Regulatory Experience with Successful Breakthrough Therapy Designation and Global Drug Approvals

SELLAS Life Sciences Strengthens Leadership Team with Appointment of Vice President Head of Regulatory Affairs

GFH009 is First CDK9 Inhibitor Monotherapy to Achieve Compete Response in Acute Myeloid Leukemia

SELLAS Announces Positive Phase 1 Data with CDK9 Inhibitor GFH009 Monotherapy in Patients with Relapsed/Refractory Hematologic Malignancies

NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Independent Data Monitoring Committee (IDMC) for its Phase 3 REGAL study for galinpepimut-S (GPS) in acute myeloid leukemia (AML) performed its initial prespecified risk-benefit assessment of unblinded data from the study and has recommended that the trial continue without modifications. The charter for the IDMC provides for periodic reviews by the IDMC for safety, efficacy and futility in addition to the interim and final analyses.

SELLAS Life Sciences' Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned

Studies are Supported and Funded Through Cooperative Agreement Grants from the National Cancer Institute

SELLAS Life Sciences' CDK9 Inhibitor GFH009 Selected for Pediatric Preclinical in Vivo Testing (PIVOT) Program in Pediatric Cancers by the National Cancer Institute

GFH009 exhibits robust activity against small cell lung cancer xenografts, both as monotherapy and in combination with PARP inhibitor olaparib

SELLAS Life Sciences' CDK9 Inhibitor GFH009 Demonstrates Tumor Growth Inhibition in Small Cell Lung Cancer Murine Model

NEW YORK, Nov. 30, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Company will present at the JMP Securities Hematology and Oncology Summit, a virtual investor conference being held from December 6-7, 2022. Angelos Stergiou, MD, ScD. h.c, President and Chief Executive Officer of SELLAS, will participate in a virtual fireside chat on Wednesday, December 7, 2022, at 3:20 p.m. ET.

SELLAS Life Sciences to Participate in the JMP Securities Hematology and Oncology Summit

– Cash Position of $21.3 Million as of September 30, 2022 –

SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2022 Financial Results

– Overall Survival Observed in Pooled Patient Data to Date Leads to Changes in Statistical Analysis Plan: Interim Analysis Now at 60 Events and Final Analysis Now at 80 Events –

SELLAS Life Sciences Announces Update on Phase 3 REGAL Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid Leukemia

- Median Overall Survival for GPS Combination (GPS in Combination with Keytruda) was 18.4 Months Compared to 13.8 months in a Checkpoint Inhibitor Single Agent Study in a Similar Patient Population Treated with Checkpoint Inhibitor Alone -

SELLAS Announces Confirmatory Top-Line Data Showing Survival and Clinical Benefits Based on the Final Analysis of the Phase 1/2 Clinical Trial of Galinpepimut-S in Combination with Keytruda® (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanced Ovarian Cancer

NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Company will present data relating to its highly selective CDK9 inhibitor, GFH009, during two poster presentations at the American Society of Hematology (ASH) Annual Meeting being held on December 10-13, 2022 in New Orleans, Louisiana. The meeting will also take place virtually.

SELLAS Life Sciences to Present Data on its Highly Selective CDK9 Inhibitor, GFH009, at the 2022 American Society of Hematology (ASH) Annual Meeting

NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provides webcast information for its virtual investor event on November 14, 2022, at 8:30 a.m. ET. at which the Company will provide an update on its Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia.

SELLAS Life Sciences Provides Webcast Information for Phase 3 REGAL Study Update on November 14, 2022

NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it will host an update call on its Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML) on November 14, 2022.

SELLAS Life Sciences to Host Update Call on Phase 3 REGAL Study on November 14, 2022

NEW YORK, Oct. 11, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that 3D Medicines Inc., SELLAS' licensee for the development and commercialization of its lead clinical candidate, galinpepimut-S (GPS), in China, Hong Kong, Macau and Taiwan, has dosed the first patient in its Phase 1 clinical trial in China of GPS (3D189 in China).

SELLAS Life Sciences' Licensee, 3D Medicines, Doses First Patient in Phase 1 Clinical Trial in China of Galinpepimut-S

NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, announced today data from a bioequivalence study for GFH009, its potent, highly selective, clinical-stage small molecule that inhibits cyclin-dependent kinase 9 (CDK9). In the ongoing Phase 1 clinical trial of GFH009 monotherapy in patients with relapsed/refractory hematologic conditions, including acute myeloid leukemia and lymphoma, GFH009 is administered intravenously as a solution. The bioequivalence study was performed to evaluate the effect of different formulations on GFH009's preclinical pharmacokinetic (PK) profile. Dr. Dragan Cicic, MD, Senior Vice President, Clinical Development, of SELLAS, presented the findings at this year's Meeting of the Society of Hematologic Oncology (SOHO) in a poster titled “Pharmacokinetics and Bioequivalence of Two Formulations of GFH009 Maleate Injection in Sprague Dawley Rats.”

SELLAS Life Sciences Presents Poster at 2022 SOHO Meeting Highlighting Bioequivalence Data for GFH009 Formulations

NEW YORK, Sept. 22, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced its upcoming poster presentation related to its highly selective CDK9 inhibitor, GFH009, at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) being held on September 28 through October 1, 2022, in Houston, Texas and virtually.

SELLAS Life Sciences Announces Poster Presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting

NEW YORK, Sept. 14, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD. h.c, President and Chief Executive Officer of SELLAS, will participate in the Cantor Oncology, Hematology, HemeOnc Conference to be held at the Lotte New York Palace in New York City on Wednesday, September 28, 2022.

SELLAS Life Sciences to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28th

- Neuroendocrine Prostate Cancer is Growing Unmet Medical Need -

SELLAS Life Sciences' Highly Selective CDK9 Inhibitor, GFH009, Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Model of Neuroendocrine Prostate Cancer Cell Line

News for SELLAS Life Sciences Group Stock (SLS)